Literature DB >> 22875604

Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.

Birgit Simell1, Anu Nurkka, Nina Ekström, Noga Givon-Lavi, Helena Käyhty, Ron Dagan.   

Abstract

In immunogenicity trials of pneumococcal conjugate vaccines (PCVs), only IgG antibody concentrations to pneumococcal capsular polysaccharides (PPSs) are usually determined, along with the opsonophagocytic activity (OPA) of antipneumococcal antibodies. We aimed to determine the role of both IgG and IgM in OPA in toddlers receiving one dose of 9-valent PCV (PCV9). The IgG and IgM antibody concentrations to PPSs of serotypes 6A, 9V, 14, 19F, and 23F were measured by enzyme immunoassay in sera from toddlers (ages 18 to 35 months) 1 month after a single PCV9 dose. The OPA for the same serotypes was measured by multiplexed opsonophagocytosis assay (MOPA). Further, IgG and IgM concentrations and MOPA were measured to PPS of serotypes 6A, 14, and 19F in sera collected 12 months after vaccination. The detected MOPA titers were high in comparison to the IgG concentrations 1 month after immunization. The IgM concentrations were higher than IgG concentrations for serotypes 6A and 14 (P < 0.001) and as high as IgG for serotypes 9V, 19F, and 23F. Correlation of the IgM antibody concentrations with MOPA (r = 0.35 to 0.65) was stronger compared to that of the IgG antibodies (r = 0.07 to 0.41). The depletion of IgG antibodies in three sets of pooled sera only slightly decreased the OPA activity against serotype 14. At 12 months after immunization, 50 to 100% of serum samples still showed detectable MOPA activity against serotypes 6A, 14, and 19F. Our results suggest that IgM contributes to OPA 1 month after a single PCV9 vaccination in toddlers and that functionally active IgM and IgG antibodies persist for at least a year.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22875604      PMCID: PMC3485875          DOI: 10.1128/CVI.00248-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  26 in total

Review 1.  Complement. First of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers.

Authors:  Ron Dagan; Noga Givon-Lavi; Orly Zamir; Merav Sikuler-Cohen; Lior Guy; Jacob Janco; Pablo Yagupsky; Drora Fraser
Journal:  J Infect Dis       Date:  2002-03-04       Impact factor: 5.226

3.  Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis.

Authors:  Birgit Simell; Arja Vuorela; Nina Ekström; Arto Palmu; Antti Reunanen; Seppo Meri; Helena Käyhty; Merja Väkeväinen
Journal:  Vaccine       Date:  2011-01-12       Impact factor: 3.641

4.  Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life.

Authors:  Sven Arne Silfverdal; Helena Skerlikova; Maria Zanova; Danica Papúchová; Magali Traskine; Dorota Borys; Lode Schuerman
Journal:  Pediatr Infect Dis J       Date:  2011-09       Impact factor: 2.129

5.  Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers.

Authors:  T Wuorimaa; R Dagan; J Eskola; J Janco; H Ahman; O Leroy; H Käyhty
Journal:  Pediatr Infect Dis J       Date:  2001-03       Impact factor: 2.129

Review 6.  The instructive role of innate immunity in the acquired immune response.

Authors:  D T Fearon; R M Locksley
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

7.  Complement receptor type three-dependent degradation of opsonized erythrocytes by mouse macrophages.

Authors:  R Rothlein; T A Springer
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  Progress toward elimination of Haemophilus influenzae type b disease among infants and children--United States, 1993-1994.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-07-28       Impact factor: 17.586

9.  Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines.

Authors:  H Peltola; T Kilpi; M Anttila
Journal:  Lancet       Date:  1992-09-05       Impact factor: 79.321

10.  Specific immunoglobulin-class antibody responses in the elderly before and after 14-valent pneumococcal vaccine.

Authors:  F L Ruben; M Uhrin
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

View more
  14 in total

Review 1.  Pneumococcal vaccine and opsonic pneumococcal antibody.

Authors:  Joon Young Song; M Allen Moseley; Robert L Burton; Moon H Nahm
Journal:  J Infect Chemother       Date:  2013-05-09       Impact factor: 2.211

2.  Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies.

Authors:  S Blumental; J C Moïsi; L Roalfe; M Zancolli; M Johnson; P Burbidge; R Borrow; S Yaro; J E Mueller; B D Gessner; D Goldblatt
Journal:  Clin Vaccine Immunol       Date:  2015-02-04

3.  IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens.

Authors:  Paul J Maglione; Noa Simchoni; Samuel Black; Lin Radigan; Jessica R Overbey; Emilia Bagiella; James B Bussel; Xavier Bossuyt; Jean-Laurent Casanova; Isabelle Meyts; Andrea Cerutti; Capucine Picard; Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

4.  Antibodies to the HMW1/HMW2 and Hia adhesins of nontypeable haemophilus influenzae mediate broad-based opsonophagocytic killing of homologous and heterologous strains.

Authors:  Linda E Winter; Stephen J Barenkamp
Journal:  Clin Vaccine Immunol       Date:  2014-02-26

Review 5.  Pneumococcal Capsular Polysaccharide Immunity in the Elderly.

Authors:  Hugh Adler; Daniela M Ferreira; Stephen B Gordon; Jamie Rylance
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

6.  The clinical relevance of IgM and IgA anti-pneumococcal polysaccharide ELISA assays in patients with suspected antibody deficiency.

Authors:  Lisanne M A Janssen; Michiel Heron; Jean-Luc Murk; Alexander C A P Leenders; Ger T Rijkers; Esther de Vries
Journal:  Clin Exp Immunol       Date:  2021-06-01       Impact factor: 4.330

7.  Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.

Authors:  Kiyoshi Migita; Yukihiro Akeda; Manabu Akazawa; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Hideko Kozuru; Yuka Jiuchi; Ryutaro Matsumura; Eiichi Suematsu; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Yasumori Izumi; Nozomi Iwanaga; Hiroshi Tsutani; Kouichirou Saisyo; Takao Yamanaka; Shiro Ohshima; Naoya Mori; Akinori Matsumori; Koichiro Takahi; Shigeru Yoshizawa; Yojiro Kawabe; Yasuo Suenaga; Tetsuo Ozawa; Norikazu Hamada; Yasuhiro Komiya; Toshihiro Matsui; Hiroshi Furukawa; Kazunori Oishi
Journal:  Arthritis Res Ther       Date:  2015-12-10       Impact factor: 5.156

8.  Impact of IgM Antibodies on Cross-Protection against Pneumococcal Serogroups 6 and 19 after Immunization with 7-Valent Pneumococcal Conjugate Vaccine in Children.

Authors:  Hye-Kyung Cho; In Ho Park; Robert L Burton; Kyung-Hyo Kim
Journal:  J Korean Med Sci       Date:  2016-04-19       Impact factor: 2.153

Review 9.  B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications.

Authors:  Tanyaporn Pattarabanjird; Cynthia Li; Coleen McNamara
Journal:  JACC Basic Transl Sci       Date:  2021-06-28

10.  Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.

Authors:  Alienke J Wijmenga-Monsuur; Els van Westen; Mirjam J Knol; Riet M C Jongerius; Marta Zancolli; David Goldblatt; Pieter G M van Gageldonk; Irina Tcherniaeva; Guy A M Berbers; Nynke Y Rots
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.